Qualigen Therapeutics, Inc. receives expected notification of deficiency from Nasdaq related to delayed filing of quarterly report on Form 10-Q
Qualigen Therapeutics (NASDAQ: QLGN) has received a deficiency notification from Nasdaq on May 19, 2025, due to its failure to file the Q1 2025 Form 10-Q on time. This notification adds to existing listing compliance issues and will be considered by the Nasdaq Hearings Panel as an additional basis for potential delisting from The Nasdaq Stock Market. The company plans to present its compliance plan at a previously scheduled hearing and is working to complete and file the delayed quarterly report. However, there is no guarantee that Nasdaq will grant an extension or that Qualigen will regain compliance with listing requirements.
Qualigen Therapeutics (NASDAQ: QLGN) ha ricevuto una notifica di inadempienza da Nasdaq il 19 maggio 2025, a causa del mancato invio tempestivo del Modulo 10-Q relativo al primo trimestre 2025. Questa notifica si aggiunge ai problemi di conformità già esistenti e sarà considerata dal Nasdaq Hearings Panel come ulteriore motivo per un possibile delisting dal Nasdaq Stock Market. L'azienda intende presentare il proprio piano di conformità durante un'udienza già programmata e sta lavorando per completare e inviare il rapporto trimestrale in ritardo. Tuttavia, non vi è alcuna garanzia che Nasdaq conceda una proroga o che Qualigen riesca a ristabilire la conformità ai requisiti di quotazione.
Qualigen Therapeutics (NASDAQ: QLGN) recibió una notificación de deficiencia por parte de Nasdaq el 19 de mayo de 2025, debido a la falta de presentación puntual del formulario 10-Q del primer trimestre de 2025. Esta notificación se suma a los problemas de cumplimiento existentes y será considerada por el Panel de Audiencias de Nasdaq como una razón adicional para un posible retiro de la cotización en The Nasdaq Stock Market. La compañía planea presentar su plan de cumplimiento en una audiencia previamente programada y está trabajando para completar y presentar el informe trimestral atrasado. Sin embargo, no hay garantía de que Nasdaq otorgue una prórroga o que Qualigen recupere el cumplimiento con los requisitos de cotización.
Qualigen Therapeutics (NASDAQ: QLGN)는 2025년 5월 19일, 2025년 1분기 10-Q 보고서 제출 지연으로 인해 Nasdaq으로부터 결함 통보를 받았습니다. 이 통보는 기존 상장 규정 미준수 문제에 추가되며, Nasdaq 심의위원회에서 나스닥 증권시장 상장 폐지 가능성에 대한 추가 사유로 고려될 예정입니다. 회사는 예정된 심의회에서 준수 계획을 제출할 예정이며, 지연된 분기 보고서를 완성하여 제출하기 위해 노력하고 있습니다. 그러나 Nasdaq이 연장 요청을 승인하거나 Qualigen이 상장 요건 준수를 회복할 것이라는 보장은 없습니다.
Qualigen Therapeutics (NASDAQ : QLGN) a reçu une notification de manquement de la part du Nasdaq le 19 mai 2025, en raison du non-dépôt dans les délais du formulaire 10-Q du premier trimestre 2025. Cette notification s’ajoute aux problèmes de conformité existants et sera prise en compte par le Nasdaq Hearings Panel comme un motif supplémentaire pouvant entraîner une radiation du Nasdaq Stock Market. La société prévoit de présenter son plan de conformité lors d’une audience déjà programmée et travaille à finaliser et déposer le rapport trimestriel en retard. Cependant, il n’y a aucune garantie que le Nasdaq accordera une prolongation ou que Qualigen retrouvera la conformité aux exigences de cotation.
Qualigen Therapeutics (NASDAQ: QLGN) erhielt am 19. Mai 2025 eine Mängelmitteilung von der Nasdaq, da das Q1 2025 Form 10-Q nicht fristgerecht eingereicht wurde. Diese Mitteilung kommt zu den bereits bestehenden Compliance-Problemen hinzu und wird vom Nasdaq Hearing Panel als weiterer Grund für eine mögliche Delistung vom Nasdaq Stock Market betrachtet. Das Unternehmen plant, seinen Compliance-Plan bei einer bereits angesetzten Anhörung vorzustellen und arbeitet daran, den verspäteten Quartalsbericht fertigzustellen und einzureichen. Es gibt jedoch keine Garantie, dass die Nasdaq eine Fristverlängerung gewährt oder dass Qualigen die Anforderungen für die Notierung wieder erfüllt.
- None.
- Failure to file Q1 2025 Form 10-Q report on time
- Additional basis for potential delisting from Nasdaq
- No guarantee of extension or regaining compliance with listing requirements
- Multiple ongoing listing compliance issues
CARLSBAD, Calif., May 19, 2025 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN) (the “Company”) announced today that it received an expected deficiency notification letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC ("Nasdaq") on May 19, 2025 (the "Notice"). The Notice indicated that the Nasdaq Hearings Panel (the “Panel”) will consider the Company’s failure to timely file its Quarterly Report on Form 10-Q for the period ended March 31, 2025 as an additional basis for delisting the Company’s securities from The Nasdaq Stock Market.
This matter serves as an additional deficiency under Nasdaq Listing Rule 5250(c)(1), which requires timely filing of all required periodic reports with the Securities and Exchange Commission (the “SEC”). As a result, this deficiency will be considered by the Panel in connection with its determination regarding the Company’s continued listing on The Nasdaq Capital Market.
Pursuant to Nasdaq Listing Rule 5810(d), the Company should present its views with respect to this additional deficiency at its previously scheduled hearing before the Panel. If the Company fails to address the aforementioned issue, the Panel will consider the record as presented at the hearing and will make its determination based on that information.
The Company intends to present its plan to regain compliance at the hearing and will continue to work diligently to complete and file the Form 10-Q as soon as practicable.
Notwithstanding the foregoing, there can be no assurance that the Panel will grant the Company a further extension or that the Company will ultimately regain compliance with all applicable requirements for continued listing.
About Qualigen Therapeutics, Inc.
For more information about Qualigen Therapeutics, Inc., please visit www.qlgntx.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are based upon current expectations or beliefs, as well as assumptions about future events. Forward-looking statements include all statements that are not historical facts and can generally be identified by terms such as “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potentially,” or “will” or similar expressions and the negatives of those terms. These statements include, but are not limited to, statements relating to the Company’s plans and expectations about the completion and filing of the 2024 Form 10-K, its submission of a plan to regain compliance with respect to the Listing Rule, and the timing thereof. Actual results could differ materially from those expressed in or implied by the forward-looking statements due to a number of risks and uncertainties, including but not limited to, uncertainties about the timing of the Company’s submission of a compliance plan, Nasdaq’s acceptance of any such plan, the duration of any extension that may be granted by Nasdaq, the potential inability to meet Nasdaq’s requirements, the Company’s preparation of the 2024 Form 10-K and the related financial statements, the possibility of additional delays in the filing of the 2024 Form 10-K, and the other risks and uncertainties described in the Company’s SEC reports and under the heading “Risk Factors” in its most recent annual report on Form 10-K and quarterly reports on Form 10-Q, which are available at www.sec.gov. These forward-looking statements speak only as of the date of this press release. Except as required by law, the Company does not undertake any obligation to update or revise its forward-looking statements to reflect events or circumstances after the date of this press release.
Contact:
Investor Relations
ir@qlgntx.com.
FAQ
Why did Qualigen Therapeutics (QLGN) receive a Nasdaq deficiency notice in May 2025?
What are the consequences of QLGN's Nasdaq deficiency notice?
What is Qualigen Therapeutics' plan to address the Nasdaq deficiency notice?
Is QLGN at risk of being delisted from Nasdaq?
